A Phase 1b First-in-human Dose Escalation and Expansion Multicenter Study of XMT-1660 in Participants with Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Previously Treated Participants With Metastatic Tnbc, Hr+/her2- Or Her2+ Breast Cancer, Endometrial Cancer, Or Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Female
  • Other Inclusion Criteria:
    1. Participant has proven recurrent or advanced solid tumor and has disease progression after treatment with available anti-cancer therapies known to confer benefit or is intolerant to treatment.
    2. Participant must have cardiac left ventricular ejection fraction =50%
    3. Participant must have adequate organ function within 14 days prior to cycle 1, day 1 of treatment
    4. ER+ breast cancer: must have had prior hormonal therapy
    5. TNBC: must have had prior chemotherapy

You may not be eligible for this study if the following are true:

    1. Participant has had major surgery within 28 days of starting study treatment, systemic anticancer therapy within the time period of 28 days.
    2. Has a diagnosis of additional malignancy that required active treatment.
    3. Participants with human immunodeficiency virus (HIV) infection are excluded from study entry. An HIV test is required during Screening.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.